These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26943041)

  • 1. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
    Zhou YY; Zhu GQ; Wang Y; Zheng JN; Ruan LY; Cheng Z; Hu B; Fu SW; Zheng MH
    Oncotarget; 2016 Apr; 7(16):21753-62. PubMed ID: 26943041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
    Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
    Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
    PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
    Lu Y; Cheng Z; Zhao Y; Chang X; Chan C; Bai Y; Cheng N
    Atherosclerosis; 2016 Nov; 254():215-227. PubMed ID: 27764723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
    Sahebkar A; Serban C; Ursoniu S; Mikhailidis DP; Undas A; Lip GY; Bittner V; Ray K; Watts GF; Hovingh GK; Rysz J; Kastelein JJ; Banach M;
    Thromb Haemost; 2016 Mar; 115(3):520-32. PubMed ID: 26632869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
    Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
    CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
    Esmeijer K; Dekkers OM; de Fijter JW; Dekker FW; Hoogeveen EK
    Sci Rep; 2019 Nov; 9(1):16632. PubMed ID: 31719617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
    Variya BC; Patel SS; Trivedi JI; Gandhi HP; Rathod SP
    Eur J Pharmacol; 2015 Oct; 764():283-291. PubMed ID: 26169562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
    Davidson M
    Prev Cardiol; 2005; 8(4):244-9. PubMed ID: 16230879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
    Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
    Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
    Xiao H; Yang CS
    Int J Cancer; 2008 Sep; 123(5):983-90. PubMed ID: 18548583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.
    Naci H; Brugts JJ; Fleurence R; Tsoi B; Toor H; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):641-57. PubMed ID: 23447425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.